Teva confirms PTAB's decisions on two patents in IPR challenge to COPAXONE® 40 mg
Teva confirmed the Patent Trial and Appeal Board decisions from an Inter Partes Review to invalidate all claims of the ‘250 and ‘413 patents for 40 mg COPAXONE® (glatiramer acetate injection). Teva plans to appeal to the U.S. Court of Appeals for the Federal Circuit. August 24, 2016